Business
Aldeyra Therapeutics Advances Investigational Oral RASP Modulator ADX‑629 Into New Phase 2 Systemic Disease Trials
Previously Announced Phase 2 Clinical Trials Initiated in Minimal Change Disease and Sjögren‑Larsson Syndrome Phase 2 Clinical Trial in Minimal Change
About this update from Aldeyra Therapeutics, Inc.
[{"type":"text","content":"\nPreviously Announced Phase 2 Clinical Trials Initiated in Minimal Change Disease and Sjögren‑Larsson Syndrome\n\nPhase 2 Clinical Trial in Minimal Change Disease Expanded to Encompass Idiopathic Nephrotic Syndrome, a Broad Group of Rare Kidney Disorders\n\nNew Phase 2 Clinical Trial Initiated in Atopic Dermatitis\n\nPreviously Announced Credit Facility Amendment Extends Cash Runway into the Second Half of 2024\n\n LEXINGTON, Mass.--(BUSINESS WIRE)--\nAldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced the initiation of Phase 2 clinical trials evaluating the safety and efficacy of ADX‑629, a novel, internally developed, investigational oral RASP modulator, for the treatment of minimal change disease and Sjögren-Larsson Syndrome. Aldeyra also announced the expansion of the minimal change disease clinical trial to encompass idiopathic nephrotic syndrome, a broad group of rare immune-mediated kidney disorders that includes minimal change disease. Additionally, Aldeyra announced the initiation of a Phase 2 clinical trial of ADX‑629 in atopic dermatitis.\n\n“Following the completion of successful proof-of-concept trials in psoriasis, asthma, COVID-19, and alcohol toxicity, the ADX‑629 trials announced today further advance the promising novel pharmacology of our proprietary RASP modulator platform for the treatment of systemic diseases,” said Todd C. Brady, M.D., Ph.D., President and Chief Executive Officer of Aldeyra. “ADX-629 has the potential to become a first-in-class therapy that may allow for convenient, non-injected, orally administered, broad-based treatment of immune-mediated diseases.\n\n“With the recently amended credit facility, we believe that our cash runway is extended into the second half of 2024 and that we are well positioned to advance our novel investigational product candidates for systemic diseases while executing on initial commercialization activities for reproxalap and ADX-2191, if approved,” Dr. Brady stated.\n\nDisease Targets\n\n\nIdiopathic Nephrotic Syndrome: Idiopathic nephrotic syndrome is comprised of a broad group of renal inflammatory diseases, including minimal change disease, and is characterized by edema, proteinuria, and hypoalbuminemia. The adaptive, multicenter, two‑part Phase 2 clinical trial will evaluate the safety and efficacy of ADX‑629 and placebo over 12 weeks of treatm...